Neurocrine Biosciences presented two-year Phase 3 data showing CRENESSITY (crinecerfont) effectively controls excess androgens and reduces glucocorticoid doses in children with classic congenital adrenal hyperplasia (CAH). The treatment led to sustained hormone improvements, including reductions in ACTH and 17-hydroxyprogesterone, and clinical benefits such as improved body mass index and insulin resistance. These results suggest CRENESSITY may improve long-term health outcomes and quality of life for pediatric CAH patients by enabling lower steroid doses and better hormonal balance. The findings build on earlier data and support CRENESSITY's role in redefining CAH treatment.
